Program

Thursday, October 3 

Welcome and Opening Keynote Talks

6:30 p.m.-8:00 p.m.

Linking genotype to phenotype in breast cancer
Joe W. Gray, OHSU Knight Cancer Institute, Portland, OR

Tumor plasticity and reactive stroma in breast cancer metastasis
Yibin Kang, Princeton University, Princeton, NJ

Opening Reception

8:00 p.m.-9:30 p.m.

Friday, October 4

Continental Breakfast

7:30 a.m.-8:30 a.m.

Session 1: Genomics/Epigenomics/“Omics”

8:30 a.m.-10:30 a.m.

Title to be announced
Samuel Aparicio, BC Cancer Research Center, Vancouver, BC, Canada

Genomic studies of breast cancer progression
Elaine Mardis, Washington University School of Medicine, St. Louis, MO

Mechanisms of estrogen receptor transcription
Jason S. Carroll, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Break

10:30 a.m.-11:00 a.m.

Session 2: Breast Cancer Models

11:00 a.m.-12:45 p.m.

Breast tumor grafts as preclinical models for antimetastasis therapy
Alana Welm, Huntsman Cancer Institute, Salt Lake City, UT

Studying therapy response and resistance in mouse models of breast cancer
Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands

Targeting tumor-initiating cells in xenograft models of human breast cancer
Michael T. Lewis, Baylor College of Medicine Cancer Center, Houston, TX

Short talk from proffered paper

Poster Session A/Lunch

1:00 p.m.-3:30 p.m.

Session 3: Stem Cells/Mammary Lineage Tracing

3:45 p.m.-5:45 p.m.

Using lineage tracing and clonal analysis to unravel mammary gland homeostasis and breast cancer initiation
Cedric Blanpain, Université Libre de Bruxelles, Brussells, Belgium

Using developmental biology to understand human breast cancer
Geoffrey M. Wahl, The Salk Institute, La Jolla, CA

Dissection of the evolving mammary epithelial hierarchy
Jane E. Visvader, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia

Wnt and Fgf signaling in mammary stem cells and breast cancer
Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX

Evening Off/Dinner on Own

5:45 p.m.-

Saturday, October 5

Continental Breakfast

7:30 a.m.-8:30 a.m.

Session 4: Tumor Dormancy and Metastasis

8:30 a.m.-10:30 a.m.

Insights into progress and therapy of metastatic breast tumors
John S. Condeelis, Sr., Albert Einstein College of Medicine, Bronx, NY

Biology and clinical implications of circulating tumor cells and bone marrow micrometastasis
Klaus Pantel, University Medical Center, Hamburg, Germany

Mechanisms of breast cancer dormancy and recurrence
Lewis A. Chodosh, University of Pennsylvania, Philadelphia, PA

Short talks from proffered papers

Break

10:30 a.m.-11:00 a.m.

Session 5: Targeted Therapies I

11:00 a.m.-12:30 p.m.

Title to be announced
Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Targeting the androgen receptor in multiple breast cancer subtypes
Jennifer K. Richer, University of Colorado Anschutz Medical Campus, Aurora, CO

Exploiting DNA repair deficiencies in breast cancer using PARP inhibitors
Andrew Tutt, King's College London, London, England

Free Time/Lunch On Own

12:30 p.m.-2:45 p.m.

Session 6: Targeted Therapies II

2:45 p.m.-4:45 p.m.

Harnessing mTOR and translational control for the clinic 
Robert J. Schneider, NYU School of Medicine, New York, NY

Translating genetic screens into new therapeutic strategies
Thomas (Trey) F. Westbrook, Baylor College of Medicine, Houston, TX

Rationale and current status of development of PI3K/TOR pathway inhibitors
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Short talks from proffered papers

Dinner On Own

4:45 p.m.-7:15 p.m.

Poster Session B/Reception

7:15 p.m.-9:45 p.m.

Sunday, October 6

Continental Breakfast

7:30 a.m.-8:30 a.m.

Session 7: Clinical Trials / Late-Breaking Research

8:30 a.m.-9:30 a.m.

Speakers to be announced

Break

9:30 a.m.-9:45 a.m.

Session 8: Tumor Microenvironment (and Immunity)

9:45 a.m.-11:45 a.m.

How tumors regulate their microenvironment in primary sites and metastasis
Zena Werb, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Title to be announced
Valerie M. Weaver, UCSF Medical Center, San Francisco, CA

Stroma-targeted immunotherapy
Stephen Gottschalk, Texas Children's Cancer and Hematology Centers, Houston, TX

Immunomodulation of breast cancer
Mary (Nora) L. Disis, University of Washington, Seattle, WA

Closing Remarks/Departure

11:45 a.m.-12:00 p.m.